Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
暂无分享,去创建一个
A. Gasbarrini | M. Kudo | J. Bruix | M. Borad | G. Abou-Alfa | R. Kelley | B. Sangro | T. Yau | Tae-You Kim | Yoon-Koo Kang | J. Bendell | A. Cheng | M. Ikeda | H. Lim | W. Yong | T. Okusaka | S. Qin | S. Damian | W. Harris | Ho Yeong Lim | N. Standifer | D. Tai | A. Negro | M. Makowsky | P. He